Literature DB >> 1311772

Phase II trial design considerations for small-cell lung cancer.

T D Moore1, E L Korn.   

Abstract

Entities:  

Mesh：

Year:  1992        PMID： 1311772     DOI： 10.1093/jnci/84.3.150

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN： 0027-8874            Impact factor:   13.506


× No keyword cloud information.
  2 in total

1.  Combination of three cytotoxic agents in small-cell lung cancer.

Authors:  G P Stathopoulos; D Trafalis; J Dimitroulis; Ch Kosmas; J Stathopoulos; D Tsavdaridis
Journal:  Cancer Chemother Pharmacol       Date:  2012-11-18       Impact factor: 3.333

2.  Phase II trial of raltitrexed ('Tomudex') in advanced small-cell lung cancer.

Authors:  P J Woll; R Basser; T Le Chevalier; P Drings; G Perez Manga; A Adenis; L Seymour; F Smith; N Thatcher
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.